Obviously we don't know whether they are planning to license PI-88 for individual cancers or a package - but if they are seeking to license individually as you point out they have completed Phase II Efficacy endpoint for Multiple Myeloma, which although is not a major cancer in the scheme of things - about 1% of all cancers, is still a major disease with about 13,000 people diagnosed in the UsA alone each year.